Welcome to BioSeeker Group!

Oncology Drug Pathway Analyzer - Online

Additional Information

Published Date Jan 1, 2016
PDF Fact Sheet View Fact Sheet for the report Oncology Drug Pathway Analyzer - Online in PDF
Format Online Access (One Year)
Publisher BioSeeker Group

Availability: In stock

$7,950.00

Quick Overview

Get instant, interactive pathway modeling on more than 3,800 cancer drugs across more than 100 different cancer types.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Oncology Drug Pathway Analyzer - Online.

    To find out more about Oncology Drug Pathway Analyzer - Online, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Oncology Drug Pathway Analyzer - Online is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Get instant, interactive pathway modeling on more than 3,800 cancer drugs across more than 100 different cancer types.

Drug targets and their pathways are the critical link between drugs and their role in the treatment of cancer. This highly unique interactive tool is based on BioSeeker’s linking of hundreds of drug targets in many different types of cancer to a wide array of pathways. The included drugs are all from early stage development to market in maturity; also featuring ceased and suspended drugs.

The Oncology Drug Pathway Analyzer is an interactive high level data tool to analyze several thousand drug-pathway connections in more than 100 different cancer indications on the fly. The tool lets you examine both single pathways and crosstalk between pathways of drugs and filter the included drugs per pathway by twelve drug specific parameters (i.e. Indication, Stage, Company, Molecular function etc.).

The Oncology Drug Pathway Analyzer is a great facilitator to realize your position and options in drug development when utilizing pathways and it significantly cuts the amount of time it takes to do so.

The following short video playlist demonstrates the use of the Pathway Analyzer when you know what pathways you are interested in, when you are unsure of which pathways you should be interested in and when you want to compare pathways. It also details what you can expect from a drug profile result.


Read more below on how to bring out the power in your pipeline and start to quickly analyze the impact of emerging pathway data in cancer by getting your own version of the Oncology Drug Pathway Analyzer.

Why you should use this tool:
- Map the competition and find suitable benchmarking drugs based on specific pathways and drug properties
- Reveal repositioning opportunities for your older, shelved drugs
- Evaluate the progression and success of targeting certain pathways for the treatment of cancer
- Investigate drugs which affect crosstalk between key pathways
- Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.
- Find possible adjuvant therapy settings with other drugs

Real case scenario (combination therapy):
In the March 20, 2012 issue of the journal Cancer Cell, researchers at The University of Texas MD Anderson Cancer Center reveal that the mTOR molecular pathway stimulates the activity of the Gli1 protein in the development and progression of esophageal cancer. Hitherto it is known that the Hedgehog pathway is the established pathway for activating Gli1. In experiments the researchers then went on to show that a combination of the mTOR inhibitor everolimus (Afinitor) and the Hedgehog inhibitor vismodegib (Erivedge) steeply reduced the tumor burden in a mouse model of esophageal adenocarcinoma.
Our tool would in seconds let you know how many and which drug are available for potential drug combination therapies in affecting both the Hedgehog- and the mTOR pathway. It also would instantly tell you which drugs is available affecting both pathways. You could then further refine the results by up to eleven drug specific parameters (i.e. Indication, Stage, Company, Molecular function etc.). There after you can view in-depth progress reports on each of the drugs of interest to you.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Oncology Drug Pathway Analyzer - Online.
    To find out more about Oncology Drug Pathway Analyzer - Online, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Oncology Drug Pathway Analyzer - Online is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More


A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More